Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Samsara has confidence it will be able to find the supply it needs

    60% confidence
  • Large customers see an opportunity to bring workflows together on one platform

    60% confidence
  • Q2 non-GAAP EPS expected to be between $0.15 and $0.16

    60% confidence
  • Samsara has only been offering Connected Asset Maintenance for a few quarters now

    60% confidence
  • Customer expansions are more driven by more assets or licenses on the same product

    60% confidence
  • In May, Samsara gathered hundreds of public sector customers at Go Beyond event in Chicago, introducing Waste Intelligence, Ground Intelligence, and Ridership Management

    60% confidence
  • Samsara thinks it will be able to keep gross margins roughly flat for FY '27

    60% confidence
  • AI/cloud cost pressure is being mitigated via COGS-related optimizations and OPEX reallocation

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Non-GTM functions may be roughly the same size, if not smaller

    60% confidence
  • Q1 was Samsara's third consecutive quarter of GAAP profitability

    60% confidence
  • Samsara raised the full-year non-GAAP operating margin target from 19% to 20%

    60% confidence
  • Q1 net new ARR was $101 million

    60% confidence
  • Samsara added $101 million in net new ARR in Q1

    60% confidence
  • There are no changes to hiring plans discussed on the last earnings call

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • Maintenance is just where Samsara is going to start with Hertz

    60% confidence
  • Europe contributed a record amount of net new ACV mix

    60% confidence
  • Samsara's guidance philosophy remains the same and is de-risked for potential downside scenarios

    60% confidence
  • DRAM and NAND supply chain conditions are a little bit tighter

    60% confidence
  • Samsara now has over $1.2 billion in ARR from customers spending $100,000 or more, growing 37% year-over-year

    60% confidence
  • Q1 was the strongest international quarter Samsara has had

    60% confidence
  • Connected Asset Maintenance helps customers shift from time-based and mileage-based maintenance schedules to a data-driven approach

    60% confidence
  • Emerging products contributed more than 20% of net new ACV for the second consecutive quarter

    60% confidence
  • GAAP EPS was a positive $0.08

    60% confidence
  • Emerging products were more than 20% of net new ACV in Q1 versus 23% of net new ACV in Q4 FY2026

    60% confidence
  • Samsara is experimenting with different pricing models for new intelligence products

    60% confidence
  • The Hertz deal covers approximately 0.5 million vehicles

    60% confidence
  • FY2027 non-GAAP operating margin expected to be 20%

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin — Source | Via News | Via News